BiotechTube

AAV2hAQP1

Phase 1Active
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Head and Neck Cancer

Conditions

Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction

Trial Timeline

May 4, 2015 → Jul 1, 2026

NCT ID
NCT02446249

About AAV2hAQP1

AAV2hAQP1 is a phase 1 stage product being developed by MeiraGTx for Squamous Cell Head and Neck Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02446249. Target conditions include Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02446249Phase 1Active

Competing Products

20 competing products in Squamous Cell Head and Neck Cancer

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
Cemiplimab + CetuximabEli LillyPhase 2
52
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
52
BB-401Benitec BiopharmaPhase 2
44
Ramucirumab + PaclitaxelEli LillyPhase 2
52
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
44
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
77
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
33
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
77
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
41
Drug Combination TherapySun PharmaceuticalPhase 2
52

Other Products from MeiraGTx

AAV RPE65Phase 1/2
33
AAV - CNGB3Phase 1/2
33
adeno-associated virus vector AAV- CNGA3Phase 1/2
33
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)Phase 1
25
AAV OPTIRPE65Pre-clinical
15